Beryl Drugs reports dip in revenue and profit for FY2025

Beryl Drugs Limited reported a total revenue of INR 2255.48 Lakhs for the financial year ended March 31, 2025, down from INR 2712.48 Lakhs in the previous year. Net profit for the period also saw a decline, reaching INR 57.88 Lakhs in FY2025 compared to INR 76.86 Lakhs in FY2024. Basic and diluted EPS per equity share stood at INR 1.14 for FY2025, down from INR 1.52 in FY2024.

The company's management attributed the decline to a temporary discontinuation of production in the FFS section for upgradation as per revised Schedule M, WHO-GMP norms, effective January 2025. Beryl Drugs did not recommend any dividend for the year, prioritizing fund conservation for future projects.

In corporate governance, Sudhir Sethi, chairman & director, is set for re-appointment, retiring by rotation at the upcoming 32nd annual general meeting on September 30, 2025.